Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market

This article was originally published in The Tan Sheet

Executive Summary

In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm
Advertisement

Related Content

FDA Warns Matrixx On Combination Supplement/Drug Products
Matrixx, H.I.G. Negotiated Deal For Nearly A Year, SEC Filings Show
Zicam Maker Matrixx' Sales Plummet While Legal Costs Climb
Novartis' Maalox Total Relief Rebranding Reflects FDA AER Evolution
FDA Says Supplement AERs Will Be Subject To Lower Threshold Before Action
FDA's "Act Now" Philosophy Has Drawbacks For Industry - CHPA Exec
FDA Enforcement Follow-Through Could Thin Out Violators
FDA says Zicam enforcement routine
Zicam Lawsuits Multiply, But Matrixx Is Confident History Will Repeat Itself
Zicam Lawsuits Multiply, But Matrixx Is Confident History Will Repeat Itself

Topics

Advertisement
UsernamePublicRestriction

Register

PS103065

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel